Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2007:217–251. doi: 10.1007/978-3-7643-7557-7_11

Genus Avipoxvirus

David B Boyle §
Editors: Andrew A Mercer4, Axel Schmidt5, Olaf Weber6
PMCID: PMC7123973

Abstract

Poxviruses identified in skin lesions of domestic, pet or wild birds are assigned largely by default to the Avipoxvirus genus within the subfamily Chordopoxvirinae of the family Poxviridae. Avipoxviruses have been identified as the causative agent of disease in at least 232 species in 23 orders of birds. Vaccines based upon attenuated avipoxvirus strains provide good disease control in production poultry, although with the large and intensive production systems there are suggestions and real risks of emergence of strains against which current vaccines might be ineffective. Sequence analysis of the whole genome has revealed overall genome structure and function resemblance to the Chordopoxvirinae; however, avipoxvirus genomes exhibit large-scale genomic rearrangements with more extensive gene families and novel host range gene in comparison with the other Chordopoxvirinae. Phylogenetic analysis places the avipoxviruses externally to the Chorodopoxvirinae to such an extent that in the future it might be appropriate to consider the Avipoxviruses as a separate subfamily within the Poxviridae. A unique relationship exists between Fowlpox virus (FWPV) and reticuloendothelosis viruses. All FWPV strains carry a remnant long terminal repeat, while field strains carry a near full-length provirus integrated at the same location in the FWPV genome. With the development of techniques to construct poxviruses expressing foreign vaccine antigens, the avipoxviruses have gone from neglected obscurity to important vaccine vectors in the past 20 years. The seminal observation of their utility for delivery of vaccine antigens to non-avian species has driven much of the interest in this group of viruses. In the veterinary area, several recombinant avipoxviruses are commercially licensed vaccines. The most successful have been those expressing glycoprotein antigens of enveloped viruses, e.g. avian influenza, Newcastle diseases and West Nile viruses. Several recombinants have undergone extensive human clinical trials as experimental vaccines against HIV/AIDS and malaria or as treatment regimens in cancer patients. The safety profile of avipoxvirus recombinants for use as veterinary and human vaccines or therapeutics is now well established.

Keywords: Long Terminal Repeat, Avian Influenza, Newcastle Disease Virus, Infectious Bronchitis Virus, Highly Pathogenic Avian Influenza

References

  • 1.van Regenmortel M.H.V., Fauquet C.M., Bishop D.H.L., Carstens E.B., Estes M.K., Lemon S.M., Maniloff J., Mayo M.A., McGeoch D.J., Pringle C.R., Wickner R.B. Virus taxonomy: The Seventh Report of the International Committee on Taxonomy of Viruses. New York: Academic Press; 2000. [Google Scholar]
  • 2.Afonso C.L., Tulman E.R., Lu Z., Zsak L., Kutish G.F., Rock D.L. The genome of fowlpox virus. J Virol. 2000;74:3815–3831. doi: 10.1128/JVI.74.8.3815-3831.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Laidlaw S.M., Skinner M.A. Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses. J Gen Virol. 2004;85:305–322. doi: 10.1099/vir.0.19568-0. [DOI] [PubMed] [Google Scholar]
  • 4.Tulman E.R., Afonso C.L., Lu Z., Zsak L., Kutish G.F., Rock D.L. The genome of canarypox virus. J Virol. 2004;78:353–366. doi: 10.1128/JVI.78.1.353-366.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Skinner M.A., Laidlaw S.M., Eldaghayes I., Kaiser P., Cottingham M.G. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines. 2005;4:63–76. doi: 10.1586/14760584.4.1.63. [DOI] [PubMed] [Google Scholar]
  • 6.Bolte A.L., Meurer J., Kaleta E.F. Avian host spectrum of avipoxviruses. Avian Pathol. 1999;28:415–432. doi: 10.1080/03079459994434. [DOI] [PubMed] [Google Scholar]
  • 7.Hertig C., Coupar B.E., Gould A.R., Boyle D.B. Field and vaccine strains of fowlpox virus carry integrated sequences from the avian retrovirus, reticuloendotheliosis virus. Virology. 1997;235:367–376. doi: 10.1006/viro.1997.8691. [DOI] [PubMed] [Google Scholar]
  • 8.Webster R.G., Taylor J., Pearson J., Rivera E., Paoletti E. Immunity to Mexican H5N2 avian influenza viruses induced by a fowl pox-H5 recombinant. Avian Dis. 1996;40:461–465. doi: 10.2307/1592246. [DOI] [PubMed] [Google Scholar]
  • 9.Swayne D.E., Beck J.R., Mickle T.R. Efficacy of recombinant fowl poxvirus vaccine in protecting chickens against a highly pathogenic Mexican-origin H5N2 avian influenza virus. Avian Dis. 1997;41:910–922. doi: 10.2307/1592346. [DOI] [PubMed] [Google Scholar]
  • 10.Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine. 1988;6:497–503. doi: 10.1016/0264-410X(88)90100-4. [DOI] [PubMed] [Google Scholar]
  • 11.Ramsay A.J., Leong K.H., Ramshaw I.A. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol Cell Biol. 1997;75:382–388. doi: 10.1038/icb.1997.60. [DOI] [PubMed] [Google Scholar]
  • 12.Leong K.H., Ramsay A.J., Boyle D.B., Ramshaw I.A. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol. 1994;68:8125–8130. doi: 10.1128/jvi.68.12.8125-8130.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol. 1998;72:10180–10188. doi: 10.1128/jvi.72.12.10180-10188.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Moorthy V.S., Imoukhuede E.B., Keating S., Pinder M., Webster D., Skinner M.A., Gilbert S.C., Walraven G., Hill A.V. Phase 1 evaluation of 3_highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis. 2004;189:2213–2219. doi: 10.1086/421118. [DOI] [PubMed] [Google Scholar]
  • 15.Tubiana R., Gomard E., Fleury H., Gougeon M.L., Mouthon B., Picolet H., Katlama C. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity. AIDS. 1997;11:819–820. [PubMed] [Google Scholar]
  • 16.Salmon-Ceron D., Excler J.L., Finkielsztejn L., Autran B., Gluckman J.C., Sicard D., Matthews T.J., Meignier B., Valentin C., El Habib R., AGIS Group and L’Agence Nationale de Recherches sur Le Sida et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AIDS Res Hum Retroviruses. 1999;15:633–645. doi: 10.1089/088922299310935. [DOI] [PubMed] [Google Scholar]
  • 17.Mayo M.A., Maniloff J., Desselberger U., Ball L.A., Fauquet C.M. Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses. New York: Academic Press; 2004. [Google Scholar]
  • 18.Luschow D., Hoffmann T., Hafez H.M. Differentiation of avian poxvirus strains on the basis of nucleotide sequences of 4b gene fragment. Avian Dis. 2004;48:453–462. doi: 10.1637/7111. [DOI] [PubMed] [Google Scholar]
  • 19.Weli S.C., Traavik T., Tryland M., Coucheron D.H., Nilssen O. Analysis and comparison of the 4b core protein gene of avipoxviruses from wild birds: evidence for interspecies spatial phylogenetic variation. Arch Virol. 2004;149:2035–2046. doi: 10.1007/s00705-004-0357-0. [DOI] [PubMed] [Google Scholar]
  • 20.McLysaght A., Baldi P.F., Gaut B.S. Extensive gene gain associated with adaptive evolution of poxviruses. Proc Natl Acad Sci USA. 2003;100:15655–15660. doi: 10.1073/pnas.2136653100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Hughes A.L., Friedman R. Poxvirus genome evolution by gene gain and loss. Mol Phylogenet Evol. 2005;35:186–195. doi: 10.1016/j.ympev.2004.12.008. [DOI] [PubMed] [Google Scholar]
  • 22.Beaudette F.R. Twenty years of progress in immunization against virus diseases of birds. J Am Vet Med Assoc. 1949;115:234–244. [Google Scholar]
  • 23.Tripathy D.N. Avipox viruses. In: McFerran J.B., McNulty M.S., editors. Virus infections of birds. London: Elsevier; 1993. pp. 5–15. [Google Scholar]
  • 24.Tripathy DN (2004) Fowl Pox. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. OIE World Organisation for Animal Health, Paris
  • 25.Walker M.H., Rup B.J., Rubin A.S., Bose H.R., Jr Specificity in the immunosuppression induced by avian reticuloendotheliosis virus. Infect Immun. 1983;40:225–235. doi: 10.1128/iai.40.1.225-235.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Nagy E., Maeda-Machang’u A.D., Krell P.J., Derbyshire J.B. Vaccination of 1-day-old chicks with fowlpox virus by the aerosol, drinking water, or cutaneous routes. Avian Dis. 1990;34:677–682. doi: 10.2307/1591263. [DOI] [PubMed] [Google Scholar]
  • 27.Deuter A., Southee D.J., Mockett A.P. Fowlpox virus: pathogenicity and vaccination of day-old chickens via the aerosol route. Res Vet Sci. 1991;50:362–364. doi: 10.1016/0034-5288(91)90142-b. [DOI] [PubMed] [Google Scholar]
  • 28.Sharma J.M., Zhang Y., Jensen D., Rautenschlein S., Yeh H.Y. Field trial in commercial broilers with a multivalent in ovo vaccine comprising a mixture of live viral vaccines against Marek’s disease, infectious bursal disease, Newcastle disease, and fowl pox. Avian Dis. 2002;46:613–622. doi: 10.1637/0005-2086(2002)046[0613:FTICBW]2.0.CO;2. [DOI] [PubMed] [Google Scholar]
  • 29.Gagic M., St Hill C.A., Sharma J.M. In ovo vaccination of specific-pathogen-free chickens with vaccines containing multiple agents. Avian Dis. 1999;43:293–301. doi: 10.2307/1592620. [DOI] [PubMed] [Google Scholar]
  • 30.Tripathy D.N., Hanson L.E. Immunity to fowlpox. Am J Vet Res. 1975;36:541–544. [PubMed] [Google Scholar]
  • 31.Morita C. Role of humoral and cell-mediated immunity on the recovery of chickens from fowlpox virus infection. J Immunol. 1973;111:1495–1501. [PubMed] [Google Scholar]
  • 32.Isa G., Pfister K., Kaaden O.R., Czerny C.P. Development of a monoclonal blocking ELISA for the detection of antibodies against fowlpox virus. J Vet Med B Infect Dis Vet Public Health. 2002;49:21–23. doi: 10.1046/j.1439-0450.2002.00533.x. [DOI] [PubMed] [Google Scholar]
  • 33.Davison F., Nair V. Use of Marek’s disease vaccines: could they be driving the virus to increasing virulence? Expert Rev Vaccines. 2005;4:77–88. doi: 10.1586/14760584.4.1.77. [DOI] [PubMed] [Google Scholar]
  • 34.Singh P., Kim T.J., Tripathy D.N. Re-emerging fowlpox: evaluation of isolates from vaccinated flocks. Avian Pathol. 2000;29:449–455. doi: 10.1080/030794500750047207. [DOI] [PubMed] [Google Scholar]
  • 35.Fatunmbi O.O., Reed W.M. Evaluation of a commercial quail pox vaccine (Bio-Pox Q) for the control of “variant” fowl poxvirus infections. Avian Dis. 1996;40:792–797. doi: 10.2307/1592300. [DOI] [PubMed] [Google Scholar]
  • 36.Fatunmbi O.O., Reed W.M. Evaluation of a commercial modified live virus fowl pox vaccine for the control of “variant” fowl poxvirus infections. Avian Dis. 1996;40:582–587. doi: 10.2307/1592268. [DOI] [PubMed] [Google Scholar]
  • 37.Tripathy D.N., Schnitzlein W.M., Morris P.J., Janssen D.L., Zuba J.K., Massey G., Atkinson C.T. Characterization of poxviruses from forest birds in Hawaii. J Wildl Dis. 2000;36:225–230. doi: 10.7589/0090-3558-36.2.225. [DOI] [PubMed] [Google Scholar]
  • 38.Smits J.E., Tella J.L., Carrete M., Serrano D., Lopez G. An epizootic of avian pox in endemic short-toed larks (Calandrella rufescens) and Berthelot’s pipits (Anthus berthelotti) in the Canary Islands, Spain. Vet Pathol. 2005;42:59–65. doi: 10.1354/vp.42-1-59. [DOI] [PubMed] [Google Scholar]
  • 39.Kim T.J., Schnitzlein W.M., McAloose D., Pessier A.P., Tripathy D.N. Characterization of an avianpox virus isolated from an Andean condor (Vultur gryphus) Vet Microbiol. 2003;96:237–246. doi: 10.1016/j.vetmic.2003.08.003. [DOI] [PubMed] [Google Scholar]
  • 40.Ghildyal N., Schnitzlein W.M., Tripathy D.N. Genetic and antigenic differences between fowlpox and quailpox viruses. Arch Virol. 1989;106:85–92. doi: 10.1007/BF01311040. [DOI] [PubMed] [Google Scholar]
  • 41.Schnitzlein W.M., Ghildyal N., Tripathy D.N. Genomic and antigenic characterization of avipoxviruses. Virus Res. 1988;10:65–75. doi: 10.1016/0168-1702(88)90058-5. [DOI] [PubMed] [Google Scholar]
  • 42.Shivaprasad H.L., Kim T.J., Woolcock P.R., Tripathy D.N. Genetic and antigenic characterization of a poxvirus isolate from ostriches. Avian Dis. 2002;46:429–436. doi: 10.1637/0005-2086(2002)046[0429:GAACOA]2.0.CO;2. [DOI] [PubMed] [Google Scholar]
  • 43.Kirmse P. Host specificity and long persistence of pox infection in the flicker (Colaptes auratus) Bull Wildlife Dis Assoc. 1967;3:14–20. [Google Scholar]
  • 44.Amano H., Morikawa S., Shimizu H., Shoji I., Kurosawa D., Matsuura Y., Miyamura T., Ueda Y. Identification of the canarypox virus thymidine kinase gene and insertion of foreign genes. Virology. 1999;256:280–290. doi: 10.1006/viro.1999.9648. [DOI] [PubMed] [Google Scholar]
  • 45.Garcia M., Narang N., Reed W.M., Fadly A.M. Molecular characterization of reticuloendotheliosis virus insertions in the genome of field and vaccine strains of fowl poxvirus. Avian Dis. 2003;47:343–354. doi: 10.1637/0005-2086(2003)047[0343:MCORVI]2.0.CO;2. [DOI] [PubMed] [Google Scholar]
  • 46.Kim T.J., Tripathy D.N. Reticuloendotheliosis virus integration in the fowl poxvirus genome: not a recent event. Avian Dis. 2001;45:663–669. doi: 10.2307/1592909. [DOI] [PubMed] [Google Scholar]
  • 47.Moore K.M., Davis J.R., Sato T., Yasuda A. Reticuloendotheliosis virus (REV) long terminal repeats incorporated in the genomes of commercial fowl poxvirus vaccines and pigeon poxviruses without indication of the presence of infectious REV. Avian Dis. 2000;44:827–841. doi: 10.2307/1593055. [DOI] [PubMed] [Google Scholar]
  • 48.Singh P., Schnitzlein W.M., Tripathy D.N. Reticuloendotheliosis virus sequences within the genomes of field strains of fowlpox virus display variability. J Virol. 2003;77:5855–5862. doi: 10.1128/JVI.77.10.5855-5862.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Tadese T., Reed W.M. Detection of specific reticuloendotheliosis virus sequence and protein from REV-integrated fowlpox virus strains. J Virol Methods. 2003;110:99–104. doi: 10.1016/S0166-0934(03)00106-X. [DOI] [PubMed] [Google Scholar]
  • 50.Ball L.A. High-frequency homologous recombination in vaccinia virus DNA. J Virol. 1987;61:1788–1795. doi: 10.1128/jvi.61.6.1788-1795.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Kriajevska M.V., Zakharova L.G., Altstein A.D. Genetic instability of vaccinia virus containing artificially duplicated genome regions. Virus Res. 1994;31:123–137. doi: 10.1016/0168-1702(94)90075-2. [DOI] [PubMed] [Google Scholar]
  • 52.Falkner F.G., Moss B. Transient dominant selection of recombinant vaccinia viruses. J Virol. 1990;64:3108–3111. doi: 10.1128/jvi.64.6.3108-3111.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Boyle D.B., Anderson M.A., Amos R., Voysey R., Coupar B.E. Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules. Biotechniques. 2004;37:104–111. doi: 10.2144/04371RR02. [DOI] [PubMed] [Google Scholar]
  • 54.Isfort R.J., Qian Z., Jones D., Silva R.F., Witter R., Kung H.J. Integration of multiple chicken retroviruses into multiple chicken herpesviruses: herpesviral gD as a common target of integration. Virology. 1994;203:125–133. doi: 10.1006/viro.1994.1462. [DOI] [PubMed] [Google Scholar]
  • 55.Fadly A.M., Witter R.L. Comparative evaluation of in vitro and in vivo assays for the detection of reticuloendotheliosis virus as a contaminant in a live virus vaccine of poultry. Avian Dis. 1997;41:695–701. doi: 10.2307/1592163. [DOI] [PubMed] [Google Scholar]
  • 56.Panicali D., Davis S.W., Weinberg R.L., Paoletti E. Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci USA. 1983;80:5364–5368. doi: 10.1073/pnas.80.17.5364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Mackett M., Smith G.L., Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA. 1982;79:7415–7419. doi: 10.1073/pnas.79.23.7415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Boyle D.B., Coupar B.E. Construction of recombinant fowlpox viruses as vectors for poultry vaccines. Virus Res. 1988;10:343–356. doi: 10.1016/0168-1702(88)90075-5. [DOI] [PubMed] [Google Scholar]
  • 59.Taylor J., Weinberg R., Kawaoka Y., Webster R.G., Paoletti E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine. 1988;6:504–508. doi: 10.1016/0264-410X(88)90101-6. [DOI] [PubMed] [Google Scholar]
  • 60.Taylor J., Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine. 1988;6:466–468. doi: 10.1016/0264-410X(88)90091-6. [DOI] [PubMed] [Google Scholar]
  • 61.Taylor J., Meignier B., Tartaglia J., Languet B., VanderHoeven J., Franchini G., Trimarchi C., Paoletti E. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995;13:539–549. doi: 10.1016/0264-410X(94)00028-L. [DOI] [PubMed] [Google Scholar]
  • 62.Baxby D., Paoletti E. Potential use of non-replicating vectors as recombinant vaccines. Vaccine. 1992;10:8–9. doi: 10.1016/0264-410X(92)90411-C. [DOI] [PubMed] [Google Scholar]
  • 63.Nelson J.B. The behaviour of poxviruses in the respiratory tract. IV. The nasal instillation of fowl pox virus in chickens and mice. J Exp Med. 1941;74:203–211. doi: 10.1084/jem.74.3.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Burnett J.W., Frothingham T.E. The cytotoxic effect of fowlpox virus on primary human amniotic cell cultures. Arch Gesamte Virusforsch. 1968;24:137–147. doi: 10.1007/BF01242907. [DOI] [PubMed] [Google Scholar]
  • 65.Somogyi P., Frazier J., Skinner M.A. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology. 1993;197:439–444. doi: 10.1006/viro.1993.1608. [DOI] [PubMed] [Google Scholar]
  • 66.Stannard L.M., Marais D., Kow D., Dumbell K.R. Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin. J Gen Virol. 1998;79:1637–1646. doi: 10.1099/0022-1317-79-7-1637. [DOI] [PubMed] [Google Scholar]
  • 67.Weli S.C., Nilssen O., Traavik T. Morphogenesis of fowlpox virus in a baby hamster kidney cell line. Med Electron Microsc. 2004;37:225–235. doi: 10.1007/s00795-004-0257-0. [DOI] [PubMed] [Google Scholar]
  • 68.Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., McConkey S.J., Poulton I., Andrews L., Andersen R.F., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA. 2005;102:4836–4841. doi: 10.1073/pnas.0406381102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.De Rose R., Chea S., Dale C.J., Reece J., Fernandez C.S., Wilson K.M., Thomson S., Ramshaw I.A., Coupar B.E., Boyle D.B., et al. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine. 2005;23:1949–1956. doi: 10.1016/j.vaccine.2004.10.012. [DOI] [PubMed] [Google Scholar]
  • 70.Gilbert P.B., Chiu Y.L., Allen M., Lawrence D.N., Chapdu C., Israel H., Holman D., Keefer M.C., Wolff M., Frey S.E. Long-term safety analysis of preventive HIV-1_vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine. 2003;21:2933–2947. doi: 10.1016/S0264-410X(03)00158-0. [DOI] [PubMed] [Google Scholar]
  • 71.Moore A.C., Hill A.V. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev. 2004;199:126–143. doi: 10.1111/j.0105-2896.2004.00138.x. [DOI] [PubMed] [Google Scholar]
  • 72.Coupar B.E., Andrew M.E., Both G.W., Boyle D.B. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur J Immunol. 1986;16:1479–1487. doi: 10.1002/eji.1830161203. [DOI] [PubMed] [Google Scholar]
  • 73.Prideaux C.T., Boyle D.B. Fowlpox virus polypeptides: sequential appearance and virion associated polypeptides. Arch Virol. 1987;96:185–199. doi: 10.1007/BF01320959. [DOI] [PubMed] [Google Scholar]
  • 74.Townsend A., Bastin J., Gould K., Brownlee G., Andrew M., Coupar B., Boyle D., Chan S., Smith G. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med. 1988;168:1211–1224. doi: 10.1084/jem.168.4.1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Niikura M., Narita T., Mikami T. Establishment and characterization of a thymidine kinase deficient avian fibroblast cell line derived from a Japanese quail cell line, QT35. J Vet Med Sci. 1991;53:439–446. doi: 10.1292/jvms.53.439. [DOI] [PubMed] [Google Scholar]
  • 76.Cowen B.S., Braune M.O. The propagation of avian viruses in a continuous cell line (QT35) of Japanese quail origin. Avian Dis. 1988;32:282–297. doi: 10.2307/1590815. [DOI] [PubMed] [Google Scholar]
  • 77.Prideaux C.T., Boyle D.B. Fowlpox virus polypeptides: sequential appearance and virion associated polypeptides. Arch Virol. 1987;96:185–199. doi: 10.1007/BF01320959. [DOI] [PubMed] [Google Scholar]
  • 78.Prideaux C.T., Kumar S., Boyle D.B. Comparative analysis of vaccinia virus promoter activity in fowlpox and vaccinia virus recombinants. Virus Res. 1990;16:43–57. doi: 10.1016/0168-1702(90)90042-A. [DOI] [PubMed] [Google Scholar]
  • 79.Boyle D.B. Quantitative assessment of poxvirus promoters in fowlpox and vaccinia virus recombinants. Virus Genes. 1992;6:281–290. doi: 10.1007/BF01702566. [DOI] [PubMed] [Google Scholar]
  • 80.Srinivasan V., Schnitzlein W.M., Tripathy D.N. A consideration of previously uncharacterized fowl poxvirus unidirectional and bidirectional late promoters for inclusion in homologous recombinant vaccines. Avian Dis. 2003;47:286–295. doi: 10.1637/0005-2086(2003)047[0286:ACOPUF]2.0.CO;2. [DOI] [PubMed] [Google Scholar]
  • 81.Dhawale S., Beisel C.E., Nazerian K. Transient expression assay for qualitative assessment of gene expression by fowlpox virus. Virus Genes. 1990;3:213–220. doi: 10.1007/BF00393181. [DOI] [PubMed] [Google Scholar]
  • 82.Kumar S., Boyle D.B. Activity of a fowlpox virus late gene promoter in vaccinia and fowlpox virus recombinants. Arch Virol. 1990;112:139–148. doi: 10.1007/BF01323160. [DOI] [PubMed] [Google Scholar]
  • 83.Vazquez-Blomquist D., Gonzalez S., Duarte C.A. Effect of promoters on cellular immune response induced by recombinant fowlpox virus expressing multi-epitope polypeptides from HIV-1. Biotechnol Appl Biochem. 2002;36:171–179. doi: 10.1042/BA20020027. [DOI] [PubMed] [Google Scholar]
  • 84.Coupar B.E., Teo T., Boyle D.B. Restriction endonuclease mapping of the fowlpox virus genome. Virology. 1990;179:159–167. doi: 10.1016/0042-6822(90)90285-Y. [DOI] [PubMed] [Google Scholar]
  • 85.Boulanger D., Baier R., Erfle V., Sutter G. Generation of recombinant fowlpox virus using the non-essential F11L orthologue as insertion site and a rapid transient selection strategy. J Virol Methods. 2002;106:141–151. doi: 10.1016/S0166-0934(02)00145-3. [DOI] [PubMed] [Google Scholar]
  • 86.Boursnell M.E., Green P.F., Campbell J.I., Deuter A., Peters R.W., Tomley F.M., Samson A.C., Emmerson P.T., Binns M.M. A fowlpox virus vaccine vector with insertion sites in the terminal repeats: demonstration of its efficacy using the fusion gene of Newcastle disease virus. Vet Microbiol. 1990;23:305–316. doi: 10.1016/0378-1135(90)90161-N. [DOI] [PubMed] [Google Scholar]
  • 87.Spehner D., Drillien R., Lecocq J.P. Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galactosidase gene and the measles virus fusion gene. J Virol. 1990;64:527–533. doi: 10.1128/jvi.64.2.527-533.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Scheiflinger F., Falkner F.G., Dorner F. Role of the fowlpox virus thymidine kinase gene for the growth of FPV recombinants in cell culture. Arch Virol. 1997;142:2421–2431. doi: 10.1007/s007050050252. [DOI] [PubMed] [Google Scholar]
  • 89.Nazerian K., Dhawale S. Structural analysis of unstable intermediate and stable forms of recombinant fowlpox virus. J Gen Virol. 1991;72:2791–2795. doi: 10.1099/0022-1317-72-11-2791. [DOI] [PubMed] [Google Scholar]
  • 90.Letellier C. Role of the TK+ phenotype in the stability of pigeonpox virus recombinant. Arch Virol. 1993;131:431–439. doi: 10.1007/BF01378643. [DOI] [PubMed] [Google Scholar]
  • 91.Coupar B.E.H., Purcell D.F.J., Thomson S.A., Ramshaw I.A., Kent S.J., Boyle D.B. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine. 2006;24:1378–1388. doi: 10.1016/j.vaccine.2005.09.044. [DOI] [PubMed] [Google Scholar]
  • 92.Domi A., Moss B. Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci USA. 2002;99:12415–12420. doi: 10.1073/pnas.192420599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Domi A., Moss B. Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage lambda-based recombination. Nat Methods. 2005;2:95–97. doi: 10.1038/nmeth734. [DOI] [PubMed] [Google Scholar]
  • 94.Hanafusa H., Hanafusa H., Kamahora J. Transformation phenomena in the pox group virus. II. Transformation between several members of pox group. 1959;2:85–91. [Google Scholar]
  • 95.Joklik W.K., Woodroofe G.M., Holmes I.H., Fenner F. The reactivation of poxviruses. I. Demonstration of the phenomenon and techniques of assay. 1960;11:168–184. doi: 10.1016/0042-6822(60)90060-x. [DOI] [PubMed] [Google Scholar]
  • 96.Harley V.R., Hudson P.J., Coupar B.E., Selleck P.W., Westbury H., Boyle D.B. Vaccinia virus expression and sequence of an avian influenza nucleoprotein gene: potential use in diagnosis. Arch Virol. 1990;113:133–141. doi: 10.1007/BF01318362. [DOI] [PubMed] [Google Scholar]
  • 97.Scheiflinger F., Dorner F., Falkner F.G. Construction of chimeric vaccinia viruses by molecular cloning and packaging. Proc Natl Acad Sci USA. 1992;89:9977–9981. doi: 10.1073/pnas.89.21.9977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Fuerst T.R., Niles E.G., Studier F.W., Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA. 1986;83:8122–8126. doi: 10.1073/pnas.83.21.8122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Das S.C., Baron M.D., Barrett T. Recovery and characterization of a chimeric rinderpest virus with the glycoproteins of peste-des-petits-ruminants virus: homologous F and H proteins are required for virus viability. J Virol. 2000;74:9039–9047. doi: 10.1128/JVI.74.19.9039-9047.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Casais R., Thiel V., Siddell S.G., Cavanagh D., Britton P. Reverse genetics system for the avian coronavirus infectious bronchitis virus. J Virol. 2001;75:12359–12369. doi: 10.1128/JVI.75.24.12359-12369.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Britton P., Green P., Kottier S., Mawditt K.L., Penzes Z., Cavanagh D., Skinner M.A. Expression of bacteriophage T7 RNA polymerase in avian and mammalian cells by a recombinant fowlpox virus. J Gen Virol. 1996;77:963–967. doi: 10.1099/0022-1317-77-5-963. [DOI] [PubMed] [Google Scholar]
  • 102.Das S.C., Baron M.D., Skinner M.A., Barrett T. Improved technique for transient expression and negative strand virus rescue using fowlpox T7 recombinant virus in mammalian cells. J Virol Methods. 2000;89:119–127. doi: 10.1016/S0166-0934(00)00210-X. [DOI] [PubMed] [Google Scholar]
  • 103.Evans S., Cavanagh D., Britton P. Utilizing fowlpox virus recombinants to generate defective RNAs of the coronavirus infectious bronchitis virus. J Gen Virol. 2000;81:2855–2865. doi: 10.1099/0022-1317-81-12-2855. [DOI] [PubMed] [Google Scholar]
  • 104.Boyle D.B., Selleck P., Heine H.G. Vaccinating chickens against avian influenza with fowlpox recombinants expressing the H7 haemagglutinin. Aust Vet J. 2000;78:44–48. doi: 10.1111/j.1751-0813.2000.tb10359.x. [DOI] [PubMed] [Google Scholar]
  • 105.Webster R.G., Kawaoka Y., Taylor J., Weinberg R., Paoletti E. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine. 1991;9:303–308. doi: 10.1016/0264-410X(91)90055-B. [DOI] [PubMed] [Google Scholar]
  • 106.Swayne D.E. Vaccines for List A poultry diseases: emphasis on avian influenza. Dev Biol. 2003;114:201–212. [PubMed] [Google Scholar]
  • 107.Qiao C.L., Yu K.Z., Jiang Y.P., Jia Y.Q., Tian G.B., Liu M., Deng G.H., Wang X.R., Meng Q.W., Tang X.Y. Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes. Avian Pathol. 2003;32:25–32. doi: 10.1080/0307945021000070688. [DOI] [PubMed] [Google Scholar]
  • 108.Swayne D.E., Garcia M., Beck J.R., Kinney N., Suarez D.L. Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert. Vaccine. 2000;18:1088–1095. doi: 10.1016/S0264-410X(99)00369-2. [DOI] [PubMed] [Google Scholar]
  • 109.Swayne D.E., Beck J.R., Kinney N. Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine. Avian Dis. 2000;44:132–137. doi: 10.2307/1592516. [DOI] [PubMed] [Google Scholar]
  • 110.Swayne D.E., Perdue M.L., Beck J.R., Garcia M., Suarez D.L. Vaccines protect chickens against H5 highly pathogenic avian influenza in the face of genetic changes in field viruses over multiple years. Vet Microbiol. 2000;74:165–172. doi: 10.1016/S0378-1135(00)00176-0. [DOI] [PubMed] [Google Scholar]
  • 111.Aldhous P., Tomlin S. Avian flu special: Avian flu: Are we ready? Nature. 2005;435:399. doi: 10.1038/435399a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Boursnell M.E., Green P.F., Samson A.C., Campbell J.I., Deuter A., Peters R.W., Millar N.S., Emmerson P.T., Binns M.M. A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV. Virology. 1990;178:297–300. doi: 10.1016/0042-6822(90)90408-J. [DOI] [PubMed] [Google Scholar]
  • 113.Iritani Y., Aoyama S., Takigami S., Hayashi Y., Ogawa R., Yanagida N., Saeki S., Kamogawa K. Antibody response to Newcastle disease virus (NDV) of recombinant fowlpox virus (FPV) expressing a hemagglutinin-neuraminidase of NDV into chickens in the presence of antibody to NDV or FPV. Avian Dis. 1991;35:659–661. doi: 10.2307/1591592. [DOI] [PubMed] [Google Scholar]
  • 114.Letellier C., Burny A., Meulemans G. Construction of a pigeonpox virus recombinant: expression of the Newcastle disease virus (NDV) fusion glycoprotein and protection of chickens against NDV challenge. Arch Virol. 1991;118:43–56. doi: 10.1007/BF01311302. [DOI] [PubMed] [Google Scholar]
  • 115.Edbauer C., Weinberg R., Taylor J., Rey-Senelonge A., Bouquet J.F., Desmettre P., Paoletti E. Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene. Virology. 1990;179:901–904. doi: 10.1016/0042-6822(90)90165-N. [DOI] [PubMed] [Google Scholar]
  • 116.Ogawa R., Yanagida N., Saeki S., Saito S., Ohkawa S., Gotoh H., Kodama K., Kamogawa K., Sawaguchi K., Iritani Y. Recombinant fowlpox viruses inducing protective immunity against Newcastle disease and fowlpox viruses. Vaccine. 1990;8:486–490. doi: 10.1016/0264-410X(90)90251-G. [DOI] [PubMed] [Google Scholar]
  • 117.Taylor J., Christensen L., Gettig R., Goebel J., Bouquet J.F., Mickle T.R., Paoletti E. Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge. Avian Dis. 1996;40:173–180. doi: 10.2307/1592386. [DOI] [PubMed] [Google Scholar]
  • 118.Taylor J., Edbauer C., Rey-Senelonge A., Bouquet J.F., Norton E., Goebel S., Desmettre P., Paoletti E. Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J Virol. 1990;64:1441–1450. doi: 10.1128/jvi.64.4.1441-1450.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Nazerian K., Yanagida N. A recombinant fowlpox virus expressing the envelope antigen of subgroup A avian leukosis/sarcoma virus. Avian Dis. 1995;39:514–520. doi: 10.2307/1591803. [DOI] [PubMed] [Google Scholar]
  • 120.Heine H.G., Foord A.J., Young P.L., Hooper P.T., Lehrbach P.R., Boyle D.B. Recombinant fowlpox virus vaccines against Australian virulent Marek’s disease virus: gene sequence analysis and comparison of vaccine efficacy in specific pathogen free and production chickens. Virus Res. 1997;50:23–33. doi: 10.1016/S0168-1702(97)00049-X. [DOI] [PubMed] [Google Scholar]
  • 121.Lee L.F., Bacon L.D., Yoshida S., Yanagida N., Zhang H.M., Witter R.L. The efficacy of recombinant fowlpox vaccine protection against Marek’s disease: its dependence on chicken line and B haplotype. Avian Dis. 2004;48:129–137. doi: 10.1637/7083. [DOI] [PubMed] [Google Scholar]
  • 122.Nazerian K., Lee L.F., Yanagida N., Ogawa R. Protection against Marek’s disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek’s disease virus. J Virol. 1992;66:1409–1413. doi: 10.1128/jvi.66.3.1409-1413.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Omar A.R., Schat K.A., Lee L.F., Hunt H.D. Cytotoxic T lymphocyte response in chickens immunized with a recombinant fowlpox virus expressing Marek’s disease herpesvirus glycoprotein B. Vet Immunol Immunopathol. 1998;62:73–82. doi: 10.1016/S0165-2427(97)00159-1. [DOI] [PubMed] [Google Scholar]
  • 124.Yanagida N., Ogawa R., Li Y., Lee L.F., Nazerian K. Recombinant fowlpox viruses expressing the glycoprotein B homolog and the pp38 gene of Marek’s disease virus. J Virol. 1992;66:1402–1408. doi: 10.1128/jvi.66.3.1402-1408.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Calvert J.G., Nazerian K., Witter R.L., Yanagida N. Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens. J Virol. 1993;67:3069–3076. doi: 10.1128/jvi.67.6.3069-3076.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Qingzhong Y., Barrett T., Brown T.D., Cook J.K., Green P., Skinner M.A., Cavanagh D. Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F) Vaccine. 1994;12:569–573. doi: 10.1016/0264-410X(94)90319-0. [DOI] [PubMed] [Google Scholar]
  • 127.Butter C., Sturman T.D., Baaten B.J., Davison T.F. Protection from infectious bursal disease virus (IBDV)-induced immunosuppression by immunization with a fowlpox recombinant containing IBDV-VP2. Avian Pathol. 2003;32:597–604. doi: 10.1080/03079450310001610686. [DOI] [PubMed] [Google Scholar]
  • 128.Shaw I., Davison T.F. Protection from IBDV-induced bursal damage by a recombinant fowlpox vaccine, fpIBD1, is dependent on the titre of challenge virus and chicken genotype. Vaccine. 2000;18:3230–3241. doi: 10.1016/S0264-410X(00)00133-X. [DOI] [PubMed] [Google Scholar]
  • 129.Boyle D.B., Heine H.G. Influence of dose and route of inoculation on responses of chickens to recombinant fowlpox virus vaccines. Vet Microbiol. 1994;41:173–181. doi: 10.1016/0378-1135(94)90146-5. [DOI] [PubMed] [Google Scholar]
  • 130.Heine H.G., Boyle D.B. Infectious bursal disease virus structural protein VP2_expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch Virol. 1993;131:277–292. doi: 10.1007/BF01378632. [DOI] [PubMed] [Google Scholar]
  • 131.Cardona C.J., Reed W.M., Witter R.L., Silva R.F. Protection of turkeys from hemorrhagic enteritis with a recombinant fowl poxvirus expressing the native hexon of hemorrhagic enteritis virus. Avian Dis. 1999;43:234–244. doi: 10.2307/1592613. [DOI] [PubMed] [Google Scholar]
  • 132.Vermeulen A.N. Progress in recombinant vaccine development against coccidiosis. A review and prospects into the next millennium. Int J Parasitol. 1998;28:1121–1130. doi: 10.1016/S0020-7519(98)00080-0. [DOI] [PubMed] [Google Scholar]
  • 133.Wang X., Schnitzlein W.M., Tripathy D.N., Girshick T., Khan M.I. Construction and immunogenicity studies of recombinant fowl poxvirus containing the S1 gene of Massachusetts 41 strain of infectious bronchitis virus. Avian Dis. 2002;46:831–838. doi: 10.1637/0005-2086(2002)046[0831:CAISOR]2.0.CO;2. [DOI] [PubMed] [Google Scholar]
  • 134.Boyle D.B. Diversified prime and boost protocols: the route to enhanced immune responses to recombinant DNA based vaccine? Aust Biotechnol. 1998;8:96–98. [Google Scholar]
  • 135.Tsukamoto K., Sato T., Saito S., Tanimura N., Hamazaki N., Mase M., Yamaguchi S. Dual-viral vector approach induced strong and long-lasting protective immunity against very virulent infectious bursal disease virus. Virology. 2000;269:257–267. doi: 10.1006/viro.2000.0184. [DOI] [PubMed] [Google Scholar]
  • 136.Karaca K., Sharma J.M., Winslow B.J., Junker D.E., Reddy S., Cochran M., McMillen J. Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses. Vaccine. 1998;16:1496–1503. doi: 10.1016/S0264-410X(97)00295-8. [DOI] [PubMed] [Google Scholar]
  • 137.Djeraba A., Musset E., Lowenthal J.W., Boyle D.B., Chausse A.M., Peloille M., Quere P. Protective effect of avian myelomonocytic growth factor in infection with Marek’s disease virus. J Virol. 2002;76:1062–1070. doi: 10.1128/JVI.76.3.1062-1070.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138.York J.J., Strom A.D., Connick T.E., McWaters P.G., Boyle D.B., Lowenthal J.W. In vivo effects of chicken myelomonocytic growth factor: delivery via a viral vector. J Immunol. 1996;156:2991–2997. [PubMed] [Google Scholar]
  • 139.Taylor J., Trimarchi C., Weinberg R., Languet B., Guillemin F., Desmettre P., Paoletti E. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine. 1991;9:190–193. doi: 10.1016/0264-410X(91)90152-V. [DOI] [PubMed] [Google Scholar]
  • 140.Taylor J., Tartaglia J., Riviere M., Duret C., Languet B., Chappuis G., Paoletti E. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination. Dev Biol Stand. 1994;82:131–135. [PubMed] [Google Scholar]
  • 141.Plotkin S.A., Cadoz M., Meignier B., Meric C., Leroy O., Excler J.L., Tartaglia J., Paoletti E., Gonczol E., Chappuis G. The safety and use of canarypox vectored vaccines. Dev Biol Stand. 1995;84:165–170. [PubMed] [Google Scholar]
  • 142.Stephensen C.B., Welter J., Thaker S.R., Taylor J., Tartaglia J., Paoletti E. Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC-and ALVAC-based CDV recombinants protect against symptomatic infection. J Virol. 1997;71:1506–1513. doi: 10.1128/jvi.71.2.1506-1513.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143.Pardo M.C., Bauman J.E., Mackowiak M. Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins. Am J Vet Res. 1997;58:833–836. [PubMed] [Google Scholar]
  • 144.Poulet H., Brunet S., Boularand C., Guiot A.L., Leroy V., Tartaglia J., Minke J., Audonnet J.C., Desmettre P. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. Vet Rec. 2003;153:141–145. doi: 10.1136/vr.153.5.141. [DOI] [PubMed] [Google Scholar]
  • 145.Minke JM, Siger L, Karaca K, Austgen L, Gordy P, Bowen R, Renshaw RW, Loosmore S, Audonnet JC, Nordgren B. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol. 2004;18:221–230. doi: 10.1007/978-3-7091-0572-6_20. [DOI] [PubMed] [Google Scholar]
  • 146.Siger L., Bowen R.A., Karaca K., Murray M.J., Gordy P.W., Loosmore S.M., Audonnet J.C., Nordgren R.M., Minke J.M. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am J Vet Res. 2004;65:1459–1462. doi: 10.2460/ajvr.2004.65.1459. [DOI] [PubMed] [Google Scholar]
  • 147.Grosenbaugh D.A., Backus C.S., Karaca K., Minke J.M., Nordgren R.M. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine. Vet Ther. 2004;5:251–257. [PubMed] [Google Scholar]
  • 148.Paoletti E., Tartaglia J., Taylor J. Safe and effective poxvirus vectors-NYVAC and ALVAC. Dev Biol Stand. 1994;82:65–69. [PubMed] [Google Scholar]
  • 149.Paoletti E., Taylor J., Meignier B., Meric C., Tartaglia J. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev Biol Stand. 1995;84:159–163. [PubMed] [Google Scholar]
  • 150.Wimsatt J., Biggins D., Innes K., Taylor B., Garell D. Evaluation of oral and subcutaneous delivery of an experimental canarypox recombinant canine distemper vaccine in the Siberian polecat (Mustela eversmanni) J Zoo Wildl Med. 2003;34:25–35. doi: 10.1638/1042-7260(2003)34[0025:EOOASD]2.0.CO;2. [DOI] [PubMed] [Google Scholar]
  • 151.Welter J., Taylor J., Tartaglia J., Paoletti E., Stephensen C.B. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. J Virol. 2000;74:6358–6367. doi: 10.1128/JVI.74.14.6358-6367.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Jones L., Tenorio E., Gorham J., Yilma T. Protective vaccination of ferrets against canine distemper with recombinant pox virus vaccines expressing the H or F genes of rinderpest virus. Am J Vet Res. 1997;58:590–593. [PubMed] [Google Scholar]
  • 153.Tartaglia J., Jarrett O., Neil J.C., Desmettre P., Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol. 1993;67:2370–2375. doi: 10.1128/jvi.67.4.2370-2375.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154.Franchini G., Gurunathan S., Baglyos L., Plotkin S., Tartaglia J. Poxvirusbased vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines. 2004;3:S75–S88. doi: 10.1586/14760584.3.4.S75. [DOI] [PubMed] [Google Scholar]
  • 155.Belshe R.B., Stevens C., Gorse G.J., Buchbinder S., Weinhold K., Sheppard H., Stablein D., Self S., McNamara J., Frey S., et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2_study in higher-and lower-risk volunteers. J Infect Dis. 2001;183:1343–1352. doi: 10.1086/319863. [DOI] [PubMed] [Google Scholar]
  • 156.de Bruyn G., Rossini A.J., Chiu Y.L., Holman D., Elizaga M.L., Frey S.E., Burke D., Evans T.G., Corey L., Keefer M.C. Safety profile of recombinant canarypox HIV vaccines. Vaccine. 2004;22:704–713. doi: 10.1016/j.vaccine.2003.08.023. [DOI] [PubMed] [Google Scholar]
  • 157.Robinson H.L., Montefiori D.C., Johnson R.P., Manson K.H., Kalish M.L., Lifson J.D., Rizvi T.A., Lu S., Hu S.L., Mazzara G.P., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med. 1999;5:526–534. doi: 10.1038/8406. [DOI] [PubMed] [Google Scholar]
  • 158.Dale C.J., De Rose R., Stratov I., Chea S., Montefiori D.C., Thomson S., Ramshaw I.A., Coupar B.E., Boyle D.B., Law M., Kent S.J. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J Virol. 2004;78:13819–13828. doi: 10.1128/JVI.78.24.13819-13828.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159.Leong K.H., Ramsay A.J., Boyle D.B., Ramshaw I.A. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol. 1994;68:8125–8130. doi: 10.1128/jvi.68.12.8125-8130.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160.Dale C.J., De Rose R., Wilson K.M., Croom H.A., Thomson S., Coupar B.E., Ramsay A., Purcell D.F., Ffrench R., Law M., et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines coexpressing IFNgamma or IL-12. Vaccine. 2004;23:188–197. doi: 10.1016/j.vaccine.2004.05.024. [DOI] [PubMed] [Google Scholar]
  • 161.Dale C.J., Zhao A., Jones S.L., Boyle D.B., Ramshaw I.A., Kent S.J. Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus coexpressing interferon-gamma. J Med Primatol. 2000;29:240–247. doi: 10.1034/j.1600-0684.2000.290317.x. [DOI] [PubMed] [Google Scholar]
  • 162.Kelleher A.D., Puls R.L., Bebbington M., Boyle D., Ffrench R., Kent S.J., Kippax S., Purcell D.F.J., Thomson S., Wand H., et al. A randomised, placebo-controlled Phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS. 2006;20:294–297. doi: 10.1097/01.aids.0000199819.40079.e9. [DOI] [PubMed] [Google Scholar]
  • 163.Cohen J. AIDS vaccines. HIV dodges one-two punch. Science. 2004;305:1545–1547. doi: 10.1126/science.305.5690.1545. [DOI] [PubMed] [Google Scholar]
  • 164.Emery S., Workman S., Puls R.L., Block M., Baker D., Bodsworth N., Anderson J., Crowe S.M., French M.A.H., Aichelburg A. o. b. o. t. N. s. t., et al. Randomised, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIG gag-pol and intereferon-gamm in HIV-1_infected subjects. Human Vaccines. 2005;1:232–238. doi: 10.4161/hv.1.6.2342. [DOI] [PubMed] [Google Scholar]
  • 165.Anderson R.J., Hannan C.M., Gilbert S.C., Laidlaw S.M., Sheu E.G., Korten S., Sinden R., Butcher G.A., Skinner M.A., Hill A.V. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol. 2004;172:3094–3100. doi: 10.4049/jimmunol.172.5.3094. [DOI] [PubMed] [Google Scholar]
  • 166.Prieur E., Gilbert S.C., Schneider J., Moore A.C., Sheu E.G., Goonetilleke N., Robson K.J., Hill A.V. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proc Natl Acad Sci USA. 2004;101:290–295. doi: 10.1073/pnas.0307158101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 167.Hodge J.W., Grosenbach D.W., Schlom J. Vector-based delivery of tumorassociated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. Cancer Detect Prev. 2002;26:275–291. doi: 10.1016/S0361-090X(02)00095-8. [DOI] [PubMed] [Google Scholar]
  • 168.Hodge J.W., Grosenbach D.W., Aarts W.M., Poole D.J., Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res. 2003;9:1837–1849. [PubMed] [Google Scholar]
  • 169.Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Topalian S.L., Sherry R.M., Restifo N.P., Wunderlich J.R., Seipp C.A., Rogers-Freezer L., et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2003;9:2973–2980. [PMC free article] [PubMed] [Google Scholar]
  • 170.Triozzi P.L., Aldrich W., Allen K.O., Lima J., Shaw D.R., Strong T.V. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma. Int J Cancer. 2005;113:406–414. doi: 10.1002/ijc.20574. [DOI] [PubMed] [Google Scholar]
  • 171.Triozzi P.L., Strong T.V., Bucy R.P., Allen K.O., Carlisle R.R., Moore S.E., Lobuglio A.F., Conry R.M. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther. 2005;16:91–100. doi: 10.1089/hum.2005.16.91. [DOI] [PubMed] [Google Scholar]

Articles from Poxviruses are provided here courtesy of Nature Publishing Group

RESOURCES